A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients.

BACKGROUND

The prevalence and types of fibroblast growth factor receptor () mutations vary significantly among different ethnic groups. The optimal application of FGFR inhibitors depends on these variations being comprehensively understood. However, such an analysis has yet to be conducted in Chinese patients.

METHODS

We retrospectively screened the genomic profiling results of 10,582 Chinese cancer patients across 16 cancer types to investigate the frequency and distribution of aberrations.

RESULTS

aberrations were identified in 745 patients, equating to an overall prevalence of 7.0%. A majority of the aberrations occurred on (56.8%), which was followed by (17.7%), (14.4%), and (2.8%). Further, 8.5% of patients had aberrations of more than 1 gene. The most common types of aberrations were amplification (53.7%), other mutations (38.8%), and fusions (5.6%). fusion and amplification occurred concurrently in 1.9% of the patients. aberrations were detected in 12 of the 16 cancers, with the highest prevalence belonging to colorectal cancer (CRC) (31%). Other -aberrant cancer types included stomach (16.8%), breast (14.3%), and esophageal (12.7%) cancer. Breast tumors were also more likely than other cancer types to have concurrent rearrangements and amplifications (P<0.001). In comparison with the public dataset, our cohort had a significantly higher number of aberrations in colorectal (P<0.001) and breast cancer (P=0.05).

CONCLUSIONS

Among the Chinese cancer patients in our study, the overall prevalence of aberrations was 7.0%. amplification was the most common genetic alteration in CRC, breast cancer, and lung cancer; while amplification was more commonly observed in gastric cancer than in other cancers in our cohort. Our study advances the understanding of the distribution of aberrations in various cancer types in the Chinese population, which will facilitate the further development of FGFR inhibitors.